– Common shares anticipated to start trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)
– ADS holders will get one normal share noted on Nasdaq for each ADS held
– Streamlined listing structure planned to allow boosted depth and breadth of ownership
COPENHAGEN, Denmark, April 08, 2026 (WORLD NEWSWIRE)– Ascendis Pharma A/S (NASDAQ: ASND) today revealed that it prepares to note its normal shares straight on Nasdaq, reliable at the opening of trading on April 20, 2026.
As part of the shift to a direct listing of normal shares on The Nasdaq Global Select Market, all exceptional ADSs will be exchanged for normal shares. Each ADS presently qualified for trading will be exchanged for one normal share, which will be noted and start trading on The Nasdaq Global Select Market under the Business’s existing ticker sign “ASND” on April 20, 2026.
” As we change into a leading worldwide biopharma business, our company believe a direct listing of our normal shares will widen access to worldwide financial investment in Ascendis,” stated Scott T. Smith, Chief Financial Officer of Ascendis Pharma. “In addition, our company believe a direct listing might likewise help with addition in particular equity indexes, which might lead to even more boosted institutional ownership and trading liquidity for ASND shares.”
Ascendis, Ascendis Pharma, the Ascendis Pharma logo design, and TransCon are hallmarks owned by the Ascendis Pharma group. © April 2026 Ascendis Pharma A/S.
(* ) Market News and Data brought to you by Benzinga APIs
To include
Benzinga News as your favored source on Google, click on this link.